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RE: Imaging Features of 
Hepato-Splenic Amyloidosis 
at PET/CT
Pier Paolo Mainenti, MD
IBB CNR, Naples 80122, Italy 
Regarding the imaging of hepatic amyloidosis with 
PET/CT, we read with interest the case report by Son and 
colleagues (1) in the Sep-Oct 2011 issue of the Korean 
Journal of Radiology. A few points need to be discussed 
with more detail. First, although the enhanced CT scan of 
the spleen exhibited a decreased and diffuse parenchymal 
attenuation, this observation was not sufficiently 
emphasized within the manuscript. The radiological 
finding of splenic hypoperfusion has been well described 
in the literature as a marker of systemic amyloidosis, 
which presents a useful clue when clinical findings fail to 
determine the proper diagnosis (2). In the case reported 
by Son and colleagues, if the radiologist had immediately 
suggested the correct diagnostic hypothesis, the patient 
would have been directed to have the the appropriate 
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laboratory examinations conducted. Specifically, the 
abdominal fat aspirate test which would have eliminated 
the need for the PET/CT scan and a risky invasive procedure 
such as a liver biopsy. 
The PET/CT images revealed a marked and diffuse increase 
in t 18F-FDG uptake in the enlarged liver. How do the 
Authors explain this finding considering the diagnosis of 
the disease which is characterized by the deposition and 
storage of an amorphous substance including amyloid? 
Did the compressed hepatic cells and the encased bile 
duct epithelium increase the glucose metabolism or was 
the amyloid deposition accompanied by the inflammation 
due to the infiltration of cells? The authors might offer us 
an hypothesis about the physio-pathological mechanism 
causing the 18F-FDG uptake in the amyloidotic liver.
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Dear Editor:
We read the letter from Dr. Mainenti regarding our case 
report (1) and we have some comments that we would 
like to address. We agreed that the splenic hypoperfusion 
on the enhanced CT scan may be a marker of systemic 
amyloidosis (2). Our radiologists also mentioned this 
finding. However, in this patient, from the PET/CT and 
liver biopsy, the possibility of hidden malignancy was 
inevitably ruled out, because the cytological exam of ascitic 
fluid that was performed at the outside hospital, before 
admission to our hospital, showed suspicious findings for 
adenocarcinoma. Repeated cytological exam of ascitic fluid, 
which was performed at our hospital, showed no evidence 
of malignancy. Further, After the PET/CT scan and liver 
biopsy, further work-up was done for systemic amyloisosis.
There were no previous studies explaining the exact 
uptake mechanism of 18F-FDG in amyloidosis. Our case 
report simply suggested that the 18F-FDG uptake was 
diffusedly increased in the liver with amyloidosis. Further 
research dealing with the uptake mechanism of 18F-FDG in 
amyloidosis is warranted.
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